While most of our results align with existing studies, the unique identification of mutations such as SAMD9L and ATP8B1 in metastatic tumors and gender-specific enrichment of CDK8 and EPHB2 are less commonly reported and may represent new areas for investigation in personalized therapeutics. This evidence concerns the gene ATP8B1 and metastatic neoplasm.